CD9 antigen on acute non-lymphoid leukemia cells: Preferential expression by promyelocytic (M3) subtype

Dario Ferrero, Nadia Carlesso, Eugenio Gallo, Patrizia Pregno, Paolo de Fabritiis, Maria Concetta Petti, Franco Mandelli

5 Scopus citations


A monoclonal antibody (S17-12), previously described to recognize subsets of myelomonocytic cells, is demonstrated to bind CD9 antigen, a surface marker of B-cell precursors, platelets and several non-hematopoietic tissues. The proportion of S17-12, CD9-positive leukemic cells was determined in 102 patients with acute non-lymphocytic leukemia. It was found to be above 75% in 14/22 M3 cases (including 3/3 of microgranular variant) and only in 1/80 cases of different FAB subtype. Complete reactivity (>95%) of leukemic clonogenic cells with CD9 MoAB was restricted to 4/18 M3 cases. Therefore, a high proportion of CD9-positive cells seems to be peculiar to M3 cases. This may help in the diagnosis of cases that lack typical morphological features.

Original languageEnglish (US)
Pages (from-to)457-461
Number of pages5
JournalLeukemia Research
Issue number6
StatePublished - 1991



  • Acute promyelocytic leukemia
  • CD9
  • CFU-L
  • monoclonal antibody

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this